+380 44 529 61 21
is the availability
Highlighting issues of treatment of hepatitis C, sofosbuvir presented at a press conference in the Column Hall of Kyiv City State Administration, the event description by correspondents of the weekly journal “Apteka”.
Corporation “PHARCO” presents a new modern molecule “Sofosbuvir” under the trade name “Grateziano”, which was officially registered in November 2015 in Ukraine.
On the 10th of December 2015 has been officially registered the pharmaceutical company “Ayapharma”.
The Verkhovna Rada of Ukraine simplified a registration procedure for the medicinal products, with the active substance registered in the developed countries. Also cut back on the length for approving the decision of Ministry of Health on drug registration up to 10 days.
On May 12-13, International Scientific-Practical Conference devoted to infectious diseases, in particular to effective schemes of complex therapy of hepatitis C by sofosbuvir was held at Kharkiv National Medical University.
Hepatitis C is an anthroponotic viral disease with parenteral route of transmission. First of all, the virus affects the kidney, thyroid or pancreas, and then goes to the liver, causing cirrhosis or cancer.